Price Target Update on Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) : Currently there are 12 street experts covering Johnson & Johnson (NYSE:JNJ) stock. The most bullish and bearish price target for the stock is $125 and $93 respectively for the short term. The average price target of all the analysts comes to $116.17. The estimated standard deviation from the target is $9.61.

Other Equity analysts have also commented on the company shares. Jefferies maintains their rating on the shares of Johnson & Johnson (NYSE:JNJ). The current rating of the shares is Hold. Equity Analysts at the Firm raises the price target to $109 per share from $108 per share. The rating by the firm was issued on June 14, 2016.

Johnson & Johnson (NYSE:JNJ): stock turned positive on Thursday. Though the stock opened at $117.2, the bulls momentum made the stock top out at $117.38 level for the day. The stock recorded a low of $116.68 and closed the trading day at $117.38, in the green by 0.79%. The total traded volume for the day was 6,775,873. The stock had closed at $116.46 in the previous days trading.

The company shares have rallied 17.49% from its 1 Year high price. On Jun 15, 2016, the shares registered one year high at $117.74 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $114.50 and the 200 Day Moving Average price is recorded at $107.55. On the companys insider trading activities, Pruden Gary J, officer (Exec VP, WW Chair, Med Devices) of Johnson & Johnson, unloaded 9,735 shares at an average price of $116.03 on June 7, 2016. The total amount of the transaction was worth $1,129,552, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.